Immatics
IMTXPhase 3Immatics is dedicated to developing transformative T-cell receptor (TCR) therapies to address the significant unmet need in solid tumors. Its core strength lies in its proprietary discovery platforms that identify novel, cancer-specific targets presented by HLA molecules, enabling the development of highly specific TCR-based therapeutics. The company has established strategic partnerships with major players like Bristol Myers Squibb and has multiple clinical-stage assets, including TCR-T cell therapies and TCR Bispecifics, positioning it at the forefront of the next wave of immuno-oncology.
IMTX · Stock Price
Historical price data
AI Company Overview
Immatics is dedicated to developing transformative T-cell receptor (TCR) therapies to address the significant unmet need in solid tumors. Its core strength lies in its proprietary discovery platforms that identify novel, cancer-specific targets presented by HLA molecules, enabling the development of highly specific TCR-based therapeutics. The company has established strategic partnerships with major players like Bristol Myers Squibb and has multiple clinical-stage assets, including TCR-T cell therapies and TCR Bispecifics, positioning it at the forefront of the next wave of immuno-oncology.
Technology Platform
Proprietary XPRESIDENT® platform for mass spectrometry-based discovery of cancer-specific peptide targets, and ACTengine® platform for developing autologous TCR-engineered T-cell therapies (TCR-T).
Pipeline Snapshot
1616 drugs in pipeline, 2 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Sunitinib + GM-CSF + Cyclophosphamide + IMA901 | Metastatic Renal Cell Carcinoma | Phase 3 |
| IMA203 + nivolumab plus relatlimab + lifileucel + nivolumab + pembrolizumab + ip... | Melanoma, Cutaneous Malignant | Phase 3 |
| Arm A: F16IL2 in combination with paclitaxel + Arm B: Paclitaxel | Merkel Cell Carcinoma | Phase 2 |
| Endoxana, IMA901, Leukine + IMA901 and Leukine | Renal Cell Carcinoma | Phase 2 |
| IMA203 Product + IMA203 product- flat dose + IMA203CD8 Product + Nivolumab | Refractory Cancer | Phase 1/2 |
Funding History
4Total raised: $288.8M
Opportunities
Risk Factors
Competitive Landscape
Immatics faces competition from established TCR players like Adaptimmune and Immunocore, as well as large pharma internal efforts. Its differentiation lies in its proprietary, proteomics-based XPRESIDENT® discovery platform, which aims to identify superior, truly cancer-specific targets, and its balanced pipeline of both cell therapies and off-the-shelf bispecifics.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile